Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib with or without Carboplatin and Paclitaxel in Advanced Lung Adenocarcinoma
NCT00126581Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2005
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in lung adenocarcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: 18 Weeks Progression Free Survival Rate. Started Aug 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT00126581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126581.